Genzyme vets raise $37.5M for a new cancer biotech

The stealthy X4 Pharmaceuticals, run by some of former Genzyme execs, has raised $37.5 million to fund its work on new cancer treatments. As Xconomy reports, the company disclosed its Series A fundraise in a regulatory filing but is otherwise staying quiet, saying only that it's at work on oral treatments for difficult-to-treat solid tumors. Genzyme and Lysosomal Therapeutics veteran Paula Ragan services as CEO of X4, and former Genzyme chief Henri Termeer is among the Cambridge, MA, company's founding advisers. More